- Needham has initiated Avadel Pharmaceuticals Plc AVDL coverage with a Buy rating and $17 price target.
- Analyst Ami Fadia sees an upside of almost 88%.
- The analyst tells investors that the Company's sodium oxybate launch and sales potential are "underappreciated."
- Fadia further contends that FT218 will be approved on PDUFA date October 15 to treat excessive daytime sleepiness and cataplexy in narcolepsy.
- The analyst also notes that the IP litigation initiated by Jazz Pharmaceuticals Plc JAZZ against Avadel shouldn't delay FT218's launch.
- Price Action: AVDL stock is up 10.50% at $9.05 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetInitiationSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefsNarcolepsy
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
